With more than 30,000 attendees, the American Society of Clinical Oncology (ASCO) annual meeting is the largest cancer conference in the world. As …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the first quarter ended March 31, 2016 “While the recent setback of the …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
Healthcare analysts expressed their views on drug makers Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Ariad Pharmaceuticals, Inc.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced new safety and immune response data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort …
Celgene Corporation (NASDAQ:CELG) announced an ANDA for its drug Abraxane yesterday. Due to the complex circumstances and probable litigation, one analyst predicts a …
As two biotech companies continue announce pipeline progressions, for better or worse, analysts weigh in on Celldex Therapeutics, Inc. (NASDAQ:CLDX) and Invivo Therapeutics …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shareholders are having a rough morning as the company’s shares are collapsing, down 51% in pre-market trading Monday, after the company announced that …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation …